FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:ATP8B4-MGMT

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: ATP8B4-MGMT
FusionPDB ID: 8271
FusionGDB2.0 ID: 8271
HgeneTgene
Gene symbol

ATP8B4

MGMT

Gene ID

79895

4255

Gene nameATPase phospholipid transporting 8B4 (putative)O-6-methylguanine-DNA methyltransferase
SynonymsATPIM-
Cytomap

15q21.2

10q26.3

Type of geneprotein-codingprotein-coding
Descriptionprobable phospholipid-transporting ATPase IMATPase, class I, type 8B, member 4P4-ATPase flippase complex alpha subunit ATP8B4potential phospholipid-transporting ATPase IMmethylated-DNA--protein-cysteine methyltransferase6-O-methylguanine-DNA methyltransferaseO-6-methylguanine-DNA-alkyltransferaseO6-methylguanine-DNA methyltransferasemethylguanine-DNA methyltransferase
Modification date2020031320200315
UniProtAcc

Q8TF62

Main function of 5'-partner protein: FUNCTION: Component of a P4-ATPase flippase complex which catalyzes the hydrolysis of ATP coupled to the transport of aminophospholipids from the outer to the inner leaflet of various membranes and ensures the maintenance of asymmetric distribution of phospholipids. Phospholipid translocation seems also to be implicated in vesicle formation and in uptake of lipid signaling molecules (Probable). {ECO:0000305}.

P16455

Main function of 5'-partner protein: FUNCTION: Involved in the cellular defense against the biological effects of O6-methylguanine (O6-MeG) and O4-methylthymine (O4-MeT) in DNA. Repairs the methylated nucleobase in DNA by stoichiometrically transferring the methyl group to a cysteine residue in the enzyme. This is a suicide reaction: the enzyme is irreversibly inactivated.
Ensembl transtripts involved in fusion geneENST idsENST00000284509, ENST00000559829, 
ENST00000558959, 
ENST00000462672, 
ENST00000306010, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score10 X 10 X 4=40019 X 11 X 7=1463
# samples 1118
** MAII scorelog2(11/400*10)=-1.86249647625006
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(18/1463*10)=-3.02286095780881
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: ATP8B4 [Title/Abstract] AND MGMT [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: ATP8B4 [Title/Abstract] AND MGMT [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)ATP8B4(50303042)-MGMT(131334505), # samples:1
Anticipated loss of major functional domain due to fusion event.ATP8B4-MGMT seems lost the major protein functional domain in Hgene partner, which is a IUPHAR drug target due to the frame-shifted ORF.
ATP8B4-MGMT seems lost the major protein functional domain in Tgene partner, which is a CGC due to the frame-shifted ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
TgeneMGMT

GO:0043066

negative regulation of apoptotic process

24147153

TgeneMGMT

GO:2000781

positive regulation of double-strand break repair

24147153



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr15:50303042/chr10:131334505)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across ATP8B4 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across MGMT (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000284509ATP8B4chr1550303042-ENST00000306010MGMTchr10131334505+22235771091212367

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000284509ENST00000306010ATP8B4chr1550303042-MGMTchr10131334505+0.0024379170.99756205

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for ATP8B4-MGMT

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
ATP8B4chr1550303042MGMTchr10131334505577154KVGDIIKLENNQFVAVLGKMDKDCEM

Top

Potential FusionNeoAntigen Information of ATP8B4-MGMT in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
ATP8B4-MGMT_50303042_131334505.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
ATP8B4-MGMTchr1550303042chr10131334505577HLA-B50:01LENNQFVA0.9760.6575715
ATP8B4-MGMTchr1550303042chr10131334505577HLA-B45:01LENNQFVAV0.99770.9789716
ATP8B4-MGMTchr1550303042chr10131334505577HLA-B50:02LENNQFVAV0.9970.7833716
ATP8B4-MGMTchr1550303042chr10131334505577HLA-B47:01LENNQFVAV0.9310.7956716
ATP8B4-MGMTchr1550303042chr10131334505577HLA-B18:01LENNQFVAV0.90640.8965716
ATP8B4-MGMTchr1550303042chr10131334505577HLA-B41:01LENNQFVAV0.73510.9882716
ATP8B4-MGMTchr1550303042chr10131334505577HLA-B50:01LENNQFVAV0.72760.7869716
ATP8B4-MGMTchr1550303042chr10131334505577HLA-B39:13LENNQFVAV0.4090.9862716
ATP8B4-MGMTchr1550303042chr10131334505577HLA-A02:13KLENNQFVAV0.99650.8383616
ATP8B4-MGMTchr1550303042chr10131334505577HLA-B40:06LENNQFVAV0.99930.7083716
ATP8B4-MGMTchr1550303042chr10131334505577HLA-B40:03LENNQFVAV0.96180.6157716
ATP8B4-MGMTchr1550303042chr10131334505577HLA-B14:03ENNQFVAVL0.60730.7474817
ATP8B4-MGMTchr1550303042chr10131334505577HLA-B39:08LENNQFVAV0.52460.9749716
ATP8B4-MGMTchr1550303042chr10131334505577HLA-B50:05LENNQFVA0.9760.6575715
ATP8B4-MGMTchr1550303042chr10131334505577HLA-B50:04LENNQFVA0.9760.6575715
ATP8B4-MGMTchr1550303042chr10131334505577HLA-B40:04LENNQFVAV0.99370.7904716
ATP8B4-MGMTchr1550303042chr10131334505577HLA-B18:05LENNQFVAV0.90640.8965716
ATP8B4-MGMTchr1550303042chr10131334505577HLA-B18:06LENNQFVAV0.88050.9306716
ATP8B4-MGMTchr1550303042chr10131334505577HLA-B18:03LENNQFVAV0.87550.8964716
ATP8B4-MGMTchr1550303042chr10131334505577HLA-B41:03LENNQFVAV0.73810.8218716
ATP8B4-MGMTchr1550303042chr10131334505577HLA-B50:05LENNQFVAV0.72760.7869716
ATP8B4-MGMTchr1550303042chr10131334505577HLA-B50:04LENNQFVAV0.72760.7869716
ATP8B4-MGMTchr1550303042chr10131334505577HLA-B18:11LENNQFVAV0.68810.883716
ATP8B4-MGMTchr1550303042chr10131334505577HLA-B39:02LENNQFVAV0.42790.987716

Top

Potential FusionNeoAntigen Information of ATP8B4-MGMT in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
ATP8B4-MGMT_50303042_131334505.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-0444VGDIIKLENNQFVAV116
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-0486ENNQFVAVLGKMDKD823
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-0706ENNQFVAVLGKMDKD823
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-0803ENNQFVAVLGKMDKD823
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-0814ENNQFVAVLGKMDKD823
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-0819VGDIIKLENNQFVAV116
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-0823ENNQFVAVLGKMDKD823
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-0825VGDIIKLENNQFVAV116
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-0825KVGDIIKLENNQFVA015
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-0827ENNQFVAVLGKMDKD823
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-0832ENNQFVAVLGKMDKD823
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-0833ENNQFVAVLGKMDKD823
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-0834VGDIIKLENNQFVAV116
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-0835ENNQFVAVLGKMDKD823
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-0836ENNQFVAVLGKMDKD823
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-0837ENNQFVAVLGKMDKD823
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-0838ENNQFVAVLGKMDKD823
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-0908ENNQFVAVLGKMDKD823
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1201VGDIIKLENNQFVAV116
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1201KVGDIIKLENNQFVA015
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1201GDIIKLENNQFVAVL217
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1203VGDIIKLENNQFVAV116
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1203KVGDIIKLENNQFVA015
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1203GDIIKLENNQFVAVL217
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1204VGDIIKLENNQFVAV116
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1204KVGDIIKLENNQFVA015
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1205VGDIIKLENNQFVAV116
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1205KVGDIIKLENNQFVA015
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1205GDIIKLENNQFVAVL217
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1206VGDIIKLENNQFVAV116
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1206KVGDIIKLENNQFVA015
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1206GDIIKLENNQFVAVL217
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1207VGDIIKLENNQFVAV116
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1207KVGDIIKLENNQFVA015
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1207GDIIKLENNQFVAVL217
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1208VGDIIKLENNQFVAV116
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1208KVGDIIKLENNQFVA015
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1208GDIIKLENNQFVAVL217
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1209VGDIIKLENNQFVAV116
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1209KVGDIIKLENNQFVA015
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1210VGDIIKLENNQFVAV116
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1210KVGDIIKLENNQFVA015
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1210GDIIKLENNQFVAVL217
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1211VGDIIKLENNQFVAV116
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1211KVGDIIKLENNQFVA015
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1211GDIIKLENNQFVAVL217
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1212VGDIIKLENNQFVAV116
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1212KVGDIIKLENNQFVA015
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1212GDIIKLENNQFVAVL217
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1213KVGDIIKLENNQFVA015
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1213VGDIIKLENNQFVAV116
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1213GDIIKLENNQFVAVL217
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1214VGDIIKLENNQFVAV116
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1214KVGDIIKLENNQFVA015
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1214GDIIKLENNQFVAVL217
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1215KVGDIIKLENNQFVA015
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1215VGDIIKLENNQFVAV116
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1215GDIIKLENNQFVAVL217
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1216VGDIIKLENNQFVAV116
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1216KVGDIIKLENNQFVA015
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1217VGDIIKLENNQFVAV116
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1217KVGDIIKLENNQFVA015
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1217GDIIKLENNQFVAVL217
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1218KVGDIIKLENNQFVA015
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1218VGDIIKLENNQFVAV116
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1218GDIIKLENNQFVAVL217
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1219VGDIIKLENNQFVAV116
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1219KVGDIIKLENNQFVA015
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1219GDIIKLENNQFVAVL217
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1220KVGDIIKLENNQFVA015
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1220VGDIIKLENNQFVAV116
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1221KVGDIIKLENNQFVA015
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1221VGDIIKLENNQFVAV116
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1221GDIIKLENNQFVAVL217
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1222VGDIIKLENNQFVAV116
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1222KVGDIIKLENNQFVA015
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1222GDIIKLENNQFVAVL217
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1223KVGDIIKLENNQFVA015
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1223VGDIIKLENNQFVAV116
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1223GDIIKLENNQFVAVL217
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1377VGDIIKLENNQFVAV116
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1377KVGDIIKLENNQFVA015
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1410VGDIIKLENNQFVAV116
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1431VGDIIKLENNQFVAV116
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1431KVGDIIKLENNQFVA015
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1448VGDIIKLENNQFVAV116
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1448KVGDIIKLENNQFVA015
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1452VGDIIKLENNQFVAV116
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1452KVGDIIKLENNQFVA015
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1501VGDIIKLENNQFVAV116
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1505VGDIIKLENNQFVAV116
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1506VGDIIKLENNQFVAV116
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1507VGDIIKLENNQFVAV116
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1507KVGDIIKLENNQFVA015
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1509VGDIIKLENNQFVAV116
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1512VGDIIKLENNQFVAV116
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1513VGDIIKLENNQFVAV116
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1516VGDIIKLENNQFVAV116
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1520VGDIIKLENNQFVAV116
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1521VGDIIKLENNQFVAV116
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1522VGDIIKLENNQFVAV116
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1524VGDIIKLENNQFVAV116
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1525VGDIIKLENNQFVAV116
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1525KVGDIIKLENNQFVA015
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1525GDIIKLENNQFVAVL217
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1528VGDIIKLENNQFVAV116
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1532VGDIIKLENNQFVAV116
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1533VGDIIKLENNQFVAV116
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1534VGDIIKLENNQFVAV116
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1535VGDIIKLENNQFVAV116
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1537VGDIIKLENNQFVAV116
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1540VGDIIKLENNQFVAV116
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1541VGDIIKLENNQFVAV116
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1542VGDIIKLENNQFVAV116
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1543VGDIIKLENNQFVAV116
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1545VGDIIKLENNQFVAV116
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1546VGDIIKLENNQFVAV116
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1548VGDIIKLENNQFVAV116
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1548KVGDIIKLENNQFVA015
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1549VGDIIKLENNQFVAV116
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1615VGDIIKLENNQFVAV116
ATP8B4-MGMTchr1550303042chr10131334505577DRB1-1615KVGDIIKLENNQFVA015

Top

Fusion breakpoint peptide structures of ATP8B4-MGMT

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
4378KLENNQFVAVLGKMATP8B4MGMTchr1550303042chr10131334505577

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of ATP8B4-MGMT

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN4378KLENNQFVAVLGKM-7.15543-7.26883
HLA-B14:023BVN4378KLENNQFVAVLGKM-4.77435-5.80965
HLA-B52:013W394378KLENNQFVAVLGKM-6.80875-6.92215
HLA-B52:013W394378KLENNQFVAVLGKM-4.20386-5.23916
HLA-A11:014UQ24378KLENNQFVAVLGKM-7.5194-8.5547
HLA-A11:014UQ24378KLENNQFVAVLGKM-6.9601-7.0735
HLA-A24:025HGA4378KLENNQFVAVLGKM-7.52403-7.63743
HLA-A24:025HGA4378KLENNQFVAVLGKM-5.82433-6.85963
HLA-B27:056PYJ4378KLENNQFVAVLGKM-3.28285-4.31815
HLA-B44:053DX84378KLENNQFVAVLGKM-5.91172-6.94702
HLA-B44:053DX84378KLENNQFVAVLGKM-4.24346-4.35686

Top

Vaccine Design for the FusionNeoAntigens of ATP8B4-MGMT

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
ATP8B4-MGMTchr1550303042chr10131334505616KLENNQFVAVGAAAATAACCAATTTGTTGCTGTACTTGGA
ATP8B4-MGMTchr1550303042chr10131334505715LENNQFVAAATAACCAATTTGTTGCTGTACTT
ATP8B4-MGMTchr1550303042chr10131334505716LENNQFVAVAATAACCAATTTGTTGCTGTACTTGGA
ATP8B4-MGMTchr1550303042chr10131334505817ENNQFVAVLAACCAATTTGTTGCTGTACTTGGAAAA

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
ATP8B4-MGMTchr1550303042chr10131334505015KVGDIIKLENNQFVAGGAGACATCATTAAATTAGAAAATAACCAATTTGTTGCTGTACTT
ATP8B4-MGMTchr1550303042chr10131334505116VGDIIKLENNQFVAVGACATCATTAAATTAGAAAATAACCAATTTGTTGCTGTACTTGGA
ATP8B4-MGMTchr1550303042chr10131334505217GDIIKLENNQFVAVLATCATTAAATTAGAAAATAACCAATTTGTTGCTGTACTTGGAAAA
ATP8B4-MGMTchr1550303042chr10131334505823ENNQFVAVLGKMDKDAACCAATTTGTTGCTGTACTTGGAAAAATGGACAAGGATTGTGAA

Top

Information of the samples that have these potential fusion neoantigens of ATP8B4-MGMT

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
BRCAATP8B4-MGMTchr1550303042ENST00000284509chr10131334505ENST00000306010TCGA-AO-A03P-01A

Top

Potential target of CAR-T therapy development for ATP8B4-MGMT

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note
HgeneATP8B4chr15:50303042chr10:131334505ENST00000284509-72845_661451193.0TransmembraneHelical
HgeneATP8B4chr15:50303042chr10:131334505ENST00000284509-72873_921451193.0TransmembraneHelical
HgeneATP8B4chr15:50303042chr10:131334505ENST00000559829-72845_661451193.0TransmembraneHelical
HgeneATP8B4chr15:50303042chr10:131334505ENST00000559829-72873_921451193.0TransmembraneHelical

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to ATP8B4-MGMT

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to ATP8B4-MGMT

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource